Special Issue

Diagnosis and Antimicrobial Treatment of *Staphylococcus* sp.

Message from the Guest Editors

Staphylococcus aureus is a Gram-positive commensal bacterium that colonizes asymptomatically different parts of the body but is also one of the major human pathogens, associated with significant morbidity and mortality worldwide. A major issue associated with S. aureus infections is the ability of S. aureus isolates to develop antibiotic resistance. Contrary to other pathogens that require a limited number of virulence factors to promote infection, S. aureus produces a striking number of toxins and other virulence factors, often responsible for several toxin-mediated diseases. The understanding of the underlining mechanisms of S. aureus biofilm formation is also pivotal for the development of new therapeutic strategies. This Special Issue is dedicated to increase our knowledge about the pathogenic mechanism of S. aureus infection, aiming at advancing the current understanding on the role of virulence factors and antibiotic resistance elements, as well as to discuss the current and novel treatment strategies under development to tackle S. aureus infection. We invite you to submit an original research article or a review related to these topics.

Guest Editors

Dr. Luís Melo

- 1. CEB-Centre of Biological Engineering, University of Minho, 4710-057 Braga, Portugal
- 2. LABBELS-Associate Laboratory, 4710-057 Braga, Portugal

Dr. Cláudia Sousa

Laboratory of Research in Biofilms Rosário Oliveira, Centre of Biological Engineering, University of Minho, Braga, Portugal

Deadline for manuscript submissions

closed (31 December 2022)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/96877

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

